Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York. CEO Eric Poma's pre-recorded presentation will be available on-demand starting September 5, 2025, at 7:00 a.m. ET.

The presentation will showcase Calidi's RedTail platform, designed to protect viruses from immune clearance, induce tumor lysis, and deliver therapeutic genetic medicines to metastatic sites through systemic administration. Dr. Poma will be available for one-on-one meetings with registered conference attendees.

SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced that its management will participate in the H.C. Wainwright 27^th Annual Global Investment Conference being held September 8 to 10, 2025, at the Lotte New York Palace Hotel in New York.

Eric Poma, Ph.D, Chief Executive Officer, has recorded a presentation that will be available as part of the on-demand session starting on September 5, 2025, at 7:00 a.m. E.T. Dr. Poma’s presentation will highlight Calidi’s RedTail platform, which is engineered to protect virus from immune clearance and induce tumor lysis and deliver potent therapeutic genetic medicines to metastatic sites through systemic administration.

Dr. Poma will be available to participate in one-on-one meetings with investors registered to attend the conference.

About Calidi Biotherapeutics

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary Redtail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations.

The lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. Additionally, Calidi is developing protected virotherapies, in clinical-stage, for intratumoral and localized administration, focusing on a subset of injectable cancer indications.

Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com or view Calidi’s Corporate Presentation here.

Forward-Looking Statements

This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “towards,” “would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning key milestones, including certain pre-clinical data, planned clinical trials, and statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s annual report filed with the SEC on Form 10-K on March 31, 2025, as may be amended or supplemented by other reports we file with the SEC from time to time. We disclaim any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

For Investors:

Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
CLDI@redchip.com

        

FAQ

When is Calidi Biotherapeutics (CLDI) presenting at the H.C. Wainwright Conference?

CEO Eric Poma's pre-recorded presentation will be available on-demand starting September 5, 2025, at 7:00 a.m. ET. The conference runs from September 8-10, 2025.

What will Calidi Biotherapeutics (CLDI) discuss at the H.C. Wainwright Conference?

The presentation will highlight Calidi's RedTail platform, which protects viruses from immune clearance, induces tumor lysis, and delivers therapeutic genetic medicines to metastatic sites.

Where is the H.C. Wainwright Conference being held for Calidi Biotherapeutics?

The conference is being held at the Lotte New York Palace Hotel in New York.

Can investors meet with Calidi Biotherapeutics (CLDI) management at the conference?

Yes, CEO Dr. Eric Poma will be available for one-on-one meetings with investors who are registered to attend the conference.